Clinical trials: Esophagus Cancer, Stage II
Squamous Cell Carcinoma of Esophagus
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
Albumin-bound paclitaxel regimen in advanced NSCLC has a better tumor response rate and safety than solvent-based paclitaxel. However, the safety and efficacy is uncertain in neoadjuvant therapy in esophageal cancer.
- Trial name
- NCT02033538
- Testing
- nanoparticle albumin-bound paclitaxel
- Where
- China
- Sponsor
- Zhejiang University
Esophageal Cancer
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00008047
- Testing
- fluorouracil, hydroxyurea, paclitaxel
- Where
- 14 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Esophageal Cancer, Gastric Cancer
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
The purpose of this study is to find out what effects, good or bad, the combination of standard chemotherapy agent paclitaxel with the investigational (experimental) drug afatinib that targets HER2, has on HER2-positive…
- Trial name
- NCT01522768
- Testing
- Afatinib and Paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma
The purpose of this study is to collect anti-tumor activity of vinorelbine when given to patients with esophageal or gastric tumors. We will also collect information on the toxicities of vinorelbine in these patients.
- Conditions
- Esophageal Cancer, Gastric Cancer, Stomach Cancer
- Trial name
- NCT00215462
- Testing
- Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer
Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Laparoscopic-assisted surgery and video-assisted thoracoscopy are less invasive types of surgery for esophageal cancer that may have fewer side effects and improve recovery.
- Trial name
- NCT00063986
- Testing
- Minimally invasive esophagectomy (MIE)
- Where
- 41 sites in United States
- Volunteers
- 110 people
- Sponsor
- Eastern Cooperative Oncology Group
Esophageal Cancer, Gastric Cancer
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent…
- Trial name
- NCT00017056
- Testing
- ixabepilone
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer
Genetic and Environmental Risk Factors Related to Esophageal Cancer
RATIONALE: Gathering information about genes, cigarette smoking, and diet may help doctors learn more about risk factors that may cause esophageal cancer.
- Trial name
- NCT01035398
- Where
- 2 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Squamous Cell Carcinoma of Esophagus
Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.
Interest of continuing systemic chemotherapy or not , after a short initial treatment (6 weeks) in patients who are in response or stable disease("Discontinuation design ")of patients with metastatic oesophageal cancer of…
- Trial name
- E-DIS (NCT01248299)
- Testing
- FU-CDDP, LV5FU2-CDDP, FOLFOX
- Where
- 17 sites in France
- Volunteers
- 105 people
- Sponsor
- Centre Oscar Lambret
Esophagus Cancer, Stomach Cancer
Effects of S-1 and Capecitabine on Coronary Artery Blood Flow
Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are occasionally associated with cardiac toxicity.
- Conditions
- Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer
- Trial name
- FluoHeart (NCT02216149)
- Testing
- S-1, Capecitabine, Oxaliplatin
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Heikki Joensuu
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment.
- Conditions
- Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma, Soft Tissue Sarcoma, Gastric/Esophageal Adenocarcinoma
- Trial name
- NCT00633789
- Testing
- brivanib
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 597 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer.
- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT01196390
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 634 sites in United States
- Volunteers
- 203 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00258297
- Testing
- gefitinib, conventional surgery, enzyme inhibitor therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Breast Cancer, Colorectal Cancer
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT) scanning before surgery, may help measure the extent of disease.
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT01254591
- Testing
- 18F-fluoromisonidazole, fluorescence angiography, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- University College London (UCL) Cancer Institute
Esophageal Cancer
Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00766480
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 20 sites in Japan
- Volunteers
- 160 people
- Sponsor
- University of Toyama
Solid Tumors
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
IMAB362 is a monoclonal antibody specific for gastric or lower esophageal adenocarcinoma. Preclinically IMAB362 was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytotoxicity…
- Trial name
- NCT01197885
- Testing
- IMAB362
- Where
- 21 sites in Bulgaria, Germany and 3 more
- Volunteers
- 54 people
- Sponsor
- Ganymed Pharmaceuticals GmbH
Esophageal Adenocarcinoma, Esophageal Cancer
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
- Trial name
- NCT05480384
- Testing
- Nivolumab, Trastuzumab deruxtecan
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Esophageal Cancer, Gastric Cancer
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or…
- Trial name
- NCT00003748
- Testing
- irinotecan hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center